title: HCV clearance and treatment outcome in genotype 1 HCV-monoinfected, HIV-coinfected and liver transplanted patients on peg-IFN-alpha-2b/ribavirin.
abstract: OBJECTIVE
  Differences in HCV-RNA clearance during therapy might explain the lower efficacy of peg-IFN/RBV in HIV/HCV-coinfection. There are limited data on HCV-RNA clearance and treatment outcomes in liver transplanted (LT) patients.
  
  
  METHODS
  To assess the rates of SVR and baseline predictors of failure after 48 weeks of weight-adjusted peg-IFN-alpha-2b/RBV in 120 patients with HCV genotype 1: 61 HCV-monoinfected, 40 HIV-coinfected and 19 LT-patients. Viral clearance was evaluated in patients completing 24 weeks of therapy (n=112, 93%).
  
  
  RESULTS
  SVR was significantly lower in HIV-coinfection than in HCV-monoinfection or LT (18 vs. 39 vs. 42%, P<0.02). By multivariate analysis, HIV-coinfection (OR 3.048, 95% CI 1.133-8.196; P=0.027), baseline HCV-RNA over 800,000 IU/ml (OR 2.800; 95% CI 1.121-6.993, P=0.027) and higher AST values (OR 1.009; 95% CI 1.001-1.018; P=0.028) were significantly associated to failure. Despite similar baseline HCV load (5.67 vs. 5.75 vs. 5.90 log10 IU/ml), HIV-coinfection showed significantly lower HCV-RNA decreases than HCV-monoinfection at weeks 4 (P=0.015), 12 (P=0.015) and 24 (P=0.0003), and than LT at weeks 12 (P=0.003) and 24 (P=0.023). 36/60 subjects (60%) reaching EVR by week 12 obtained SVR vs. 3/60 (5%) who did not.
  
  
  CONCLUSIONS
  HIV-coinfection was independently associated to treatment failure, and led to a significantly slower HCV-RNA clearance.
authors.affiliation: Service of Infectious Diseases, Hospital Ramón y Cajal, Universidad de Alcalá de Henares, Madrid, Spain. amoreno.hrc@salud.madrid.org
authors.forename: Ana
authors.initials: A
authors.lastname: Moreno
authors.forename: Rafael
authors.initials: R
authors.lastname: Bárcena
authors.forename: Silvia
authors.initials: S
authors.lastname: García-Garzón
authors.forename: Alfonso
authors.initials: A
authors.lastname: Muriel
authors.forename: Carmen
authors.initials: C
authors.lastname: Quereda
authors.forename: Leonor
authors.initials: L
authors.lastname: Moreno
authors.forename: María L
authors.initials: ML
authors.lastname: Mateos
authors.forename: Jesús
authors.initials: J
authors.lastname: Fortún
authors.forename: Pilar
authors.initials: P
authors.lastname: Martín-Dávila
authors.forename: Miguel
authors.initials: M
authors.lastname: García
authors.forename: Carlos
authors.initials: C
authors.lastname: Blesa
authors.forename: Elena
authors.initials: E
authors.lastname: Otón
authors.forename: Alberto
authors.initials: A
authors.lastname: Moreno
authors.forename: Santiago
authors.initials: S
authors.lastname: Moreno
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D015897:Comorbidity; D004359:Drug Therapy, Combination; D005838:Genotype; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy; D006679:HIV Seropositivity; D016174:Hepacivirus / Q000378:metabolism; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols; D012367:RNA, Viral; D011994:Recombinant Proteins; D012254:Ribavirin / Q000627:therapeutic use*; D016896:Treatment Outcome; D019562:Viral Load; D014766:Viremia
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b